DK3332789T3 - Cladribinkur til behandling af multipel sklerose - Google Patents

Cladribinkur til behandling af multipel sklerose Download PDF

Info

Publication number: DK3332789T3
Authority: DK; Denmark
Prior art keywords: cladribincur; treatment; multiple sclerosis; sclerosis
Prior art date: 2004-12-22

Application number

DK18151634.5T

Other languages

English (en)

Inventor

Luca Giampiero De

Amaud Ythier

Alain Munafo

Maria Lopez-Bresnahan

Original Assignee

Merck Serono Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2005-12-20

Publication date

2022-07-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3332789(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-20 Application filed by Merck Serono Sa filed Critical Merck Serono Sa

2022-07-11 Application granted granted Critical

2022-07-11 Publication of DK3332789T3 publication Critical patent/DK3332789T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DK18151634.5T 2004-12-22 2005-12-20 Cladribinkur til behandling af multipel sklerose DK3332789T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US63866904P	2004-12-22	2004-12-22
EP04106909		2004-12-22
EP14001970.4A EP2805723B1 (en)	2004-12-22	2005-12-20	Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number	Publication Date
DK3332789T3 true DK3332789T3 (da)	2022-07-11

Family

ID=36227798

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK22166610.0T DK4070800T3 (da)	2004-12-22	2005-12-20	Cladribinkur til behandling af multipel sklerose
DK18151634.5T DK3332789T3 (da)	2004-12-22	2005-12-20	Cladribinkur til behandling af multipel sklerose
DK14001970.4T DK2805723T3 (da)	2004-12-22	2005-12-20	Cladribin-regime til behandling af multipel sclerose

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK22166610.0T DK4070800T3 (da)	2004-12-22	2005-12-20	Cladribinkur til behandling af multipel sklerose

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK14001970.4T DK2805723T3 (da)	2004-12-22	2005-12-20	Cladribin-regime til behandling af multipel sclerose

Country Status (25)

Country	Link
US (2)	US7713947B2 (da)
EP (7)	EP3332789B1 (da)
JP (7)	JP5795456B2 (da)
KR (1)	KR20070091662A (da)
AR (1)	AR052830A1 (da)
AU (2)	AU2005318190B2 (da)
BR (1)	BRPI0517132B8 (da)
CA (2)	CA2588966C (da)
CY (3)	CY1112614T1 (da)
DK (3)	DK4070800T3 (da)
EA (1)	EA015799B1 (da)
ES (2)	ES2921858T3 (da)
FI (1)	FI4070800T3 (da)
FR (1)	FR18C1008I2 (da)
HR (1)	HRP20120228T1 (da)
HU (3)	HUE059133T2 (da)
IL (2)	IL183930A0 (da)
LT (3)	LT4070800T (da)
LU (1)	LUC00064I2 (da)
MX (1)	MX2007007610A (da)
NO (1)	NO20073813L (da)
PL (4)	PL2805723T3 (da)
SG (1)	SG160391A1 (da)
SI (3)	SI2805723T1 (da)
WO (1)	WO2006067141A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK4070800T3 (da)	2004-12-22	2025-01-02	Merck Serono Sa	Cladribinkur til behandling af multipel sklerose
AU2007253254B2 (en)	2006-05-24	2013-01-17	Merck Serono Sa	Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en)	2009-12-23	2011-07-13	Merck Serono S.A.	Use of purine analogues for treating airway diseases
WO2011117267A1 (en)	2010-03-24	2011-09-29	Merck Serono Sa	Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en)	2010-09-08	2012-03-14	Merck Serono S.A.	Oral administration of nucleoside monophosphates
WO2012097867A1 (en)	2011-01-18	2012-07-26	Synthon Bv	Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) *	2014-01-29	2014-03-12	Roach Arthur H	Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) *	2017-07-21	2019-01-23	Chord Therapeutics S A R L	Use of cladribine for treating autoimmune neuromuscular disease
TWI869330B (zh) *	2017-11-24	2025-01-11	德商馬克專利公司	用於治療進展型多發性硬化症之克拉屈濱(cladribine)療程
GB2601786A (en) *	2020-12-10	2022-06-15	Chord Therapeutics S A R L	Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1269659A (en)	1984-08-06	1990-05-29	Brigham Young University	Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) *	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) *	1988-06-27	1990-10-23	Bloom Philip M	Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en)	1991-12-18	1993-05-04	Ortho Pharmaceutical Corporation	Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en)	1994-12-21	1997-06-24	Ortho Pharmaceutical Corporation	Stable 2-chloro-2'-deoxyadenosine formulations
ES2182920T3 (es)	1994-12-22	2003-03-16	Ortho Pharma Corp	Formulaciones solubles de 2-cloro02'-deoxiadenosina.
US6194395B1 (en)	1999-02-25	2001-02-27	Orthro-Mcneil Pharmaceutical, Inc.	Cyclodextrin cladribine formulations
WO2000064918A1 (en)	1999-04-28	2000-11-02	Sterrenbeld Biotechnologie North America, Inc.	METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) *	2002-08-13	2004-03-04	Medac Gesellschaft für klinische Spezialpräparate mbH	Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
AU2003275267A1 (en)	2002-09-25	2004-04-19	Brigham Young University, Technology Transfer Office	Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine
GB2394658A (en) *	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
KR20060002758A (ko) *	2003-02-25	2006-01-09	어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.	탈수초 질환에서 리바비린과 인터페론 베타의 병용
CA2520523C (en)	2003-03-28	2011-10-11	Ivax Corporation	Oral formulations of cladribine
CN101912615B (zh)	2003-03-28	2013-03-27	阿莱斯贸易有限公司	用于改善的经口和透粘膜输送的克拉屈滨制剂
DK4070800T3 (da)	2004-12-22	2025-01-02	Merck Serono Sa	Cladribinkur til behandling af multipel sklerose
AU2007253254B2 (en) *	2006-05-24	2013-01-17	Merck Serono Sa	Cladribine regimen for treating multiple sclerosis

2005
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Expired - Lifetime
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en active Pending
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending

Also Published As

Publication number	Publication date
EP1827461B1 (en)	2012-02-29
ES2921858T3 (es)	2022-09-01
EP2805723A1 (en)	2014-11-26
PL4070800T3 (pl)	2025-03-10
NO20073813L (no)	2007-09-21
CA2588966C (en)	2020-07-21
BRPI0517132A (pt)	2008-09-30
JP2016138128A (ja)	2016-08-04
IL183930A0 (en)	2007-10-31
FR18C1008I1 (da)	2018-03-30
EP4070800B1 (en)	2024-10-16
LT4070800T (lt)	2025-01-10
IL212421A0 (en)	2011-06-30
EP4070800A1 (en)	2022-10-12
HUE059133T2 (hu)	2022-10-28
JP6092945B2 (ja)	2017-03-08
EP2805723B1 (en)	2018-01-17
JP2008524313A (ja)	2008-07-10
EP2275110B1 (en)	2013-07-10
EP4523753A3 (en)	2025-05-28
US7713947B2 (en)	2010-05-11
EP2263678B1 (en)	2014-06-11
EP4523753A2 (en)	2025-03-19
JP6290962B2 (ja)	2018-03-07
PL3332789T3 (pl)	2022-08-22
AU2005318190A1 (en)	2006-06-29
US8377903B2 (en)	2013-02-19
SG160391A1 (en)	2010-04-29
LUC00064I1 (da)	2018-02-14
CA3087419C (en)	2023-03-07
LUC00064I2 (da)	2018-03-28
EP2263678A2 (en)	2010-12-22
EP1827461A1 (en)	2007-09-05
HUE070333T2 (hu)	2025-05-28
AU2011200768B2 (en)	2012-09-13
CY2018006I1 (el)	2018-06-27
LTC2805723I2 (lt)	2022-04-25
CA3087419A1 (en)	2006-06-29
IL212421A (en)	2014-01-30
HUS1800009I1 (hu)	2018-05-02
JP6430554B2 (ja)	2018-11-28
WO2006067141A1 (en)	2006-06-29
SI2805723T1 (en)	2018-02-28
EP3332789A1 (en)	2018-06-13
JP2017101061A (ja)	2017-06-08
CA2588966A1 (en)	2006-06-29
JP5795456B2 (ja)	2015-10-14
BRPI0517132B8 (pt)	2021-05-25
LT3332789T (lt)	2022-07-25
EP2275110A3 (en)	2011-04-27
SI4070800T1 (sl)	2025-03-31
AR052830A1 (es)	2007-04-04
DK2805723T3 (da)	2018-01-29
EP2275110A2 (en)	2011-01-19
US20100203017A1 (en)	2010-08-12
FR18C1008I2 (fr)	2019-03-01
JP2015180685A (ja)	2015-10-15
BRPI0517132B1 (pt)	2020-02-18
CY1119790T1 (el)	2018-06-27
HRP20120228T1 (hr)	2012-04-30
CY1112614T1 (el)	2016-02-10
JP2020193206A (ja)	2020-12-03
CY2018006I2 (el)	2018-06-27
JP5908863B2 (ja)	2016-04-26
JP2013216664A (ja)	2013-10-24
AU2005318190B2 (en)	2010-11-25
LTPA2018503I1 (lt)	2018-03-12
SI3332789T1 (sl)	2022-08-31
EA015799B1 (ru)	2011-12-30
AU2011200768A1 (en)	2011-03-17
PL2805723T3 (pl)	2018-04-30
EA200701221A1 (ru)	2008-02-28
PL1827461T3 (pl)	2012-07-31
DK4070800T3 (da)	2025-01-02
FI4070800T3 (fi)	2025-01-14
EP3332789B1 (en)	2022-04-06
KR20070091662A (ko)	2007-09-11
EP2263678A3 (en)	2011-04-27
JP2018165271A (ja)	2018-10-25
US20090081163A1 (en)	2009-03-26
ES3007339T3 (en)	2025-03-19
MX2007007610A (es)	2007-08-03

Publication	Publication Date	Title
DK1828164T3 (da)	2008-12-08	Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da)	2013-09-30	Fremgangsmåde til fremstilling af dihydropteridion
DK1701941T3 (da)	2012-08-13	Forbindelser til behandling af sygdomme med celleproliferation
DK1720571T3 (da)	2012-09-03	Fremgangsmåde til behandling af hæmolytisk sygdom
DK2137537T3 (da)	2013-07-29	Sammensætninger og anvendelser til behandling af multipel sklerose
DK2308507T3 (da)	2015-04-20	Fremgangsmåder til behandling af præeklampsi
DK1720866T3 (da)	2011-11-21	Fremgangsmåde
DK1755661T3 (da)	2014-06-16	Gelsolin til anvendelse til behandling af infektioner
DK1893586T3 (da)	2009-01-05	Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1567152T3 (da)	2013-10-07	Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
DK1928438T3 (da)	2013-04-22	Anvendelse af ibudilast til behandling af stofafhængighed
DK1708992T3 (da)	2007-11-05	Sulfonamidderivater til behandling af sygdomme
DK3403657T3 (da)	2022-02-28	Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1801108T3 (da)	2013-02-18	Morpholinforbindelser til behandling af inflammationer.
DK3332789T3 (da)	2022-07-11	Cladribinkur til behandling af multipel sklerose
DK1763520T3 (da)	2009-02-09	Anvendelse af trisubstituerede benzopyranoner
DK1687297T3 (da)	2014-09-22	Triazindimerer til behandling af autoimmunsygdomme
DK1709082T3 (da)	2014-06-16	Sammensætning til behandling af patologi knyttet til MSRV/HERV-W
DK1541137T3 (da)	2010-04-26	Transdermalt delivery system af gestoden
DK1831223T3 (da)	2013-06-10	Fremgangsmåde til fremstilling af L-biopterin
DK1814555T3 (da)	2009-12-07	S-mirtazapin til behandling af hedeture
DK1789529T3 (da)	2013-11-11	Fremgangsmåde til forbedring af konserveringen af lactococcus
DK1812002T3 (da)	2012-02-06	Behandling af mastitis
DK1692137T3 (da)	2007-04-30	Fremgangsmåde til fremstilling af tubulinininhibitorer
SE0400476L (sv)	2005-08-28	Komponent